articleThe LancetApr 22, 2013GREEN OA

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

Royal Marsden NHS Foundation Trust · St James's University Hospital · +12 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

554
total citations
FWCI
33.18
Percentile
100%
References
38
Citations per year

Authors

16

Topics & keywords

Keywords
  • Vincristine
  • CHOP
  • Rituximab
  • Medicine
  • Prednisolone
  • Cyclophosphamide
  • Gastroenterology
  • Lymphoma
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.